Haleon PLC ( (GB:HLN) ) has provided an announcement.
Haleon PLC has agreed to purchase 44,155,844 ordinary shares from Pfizer Inc. as part of an off-market transaction, marking Pfizer’s complete exit from its stake in Haleon. This move aligns with Haleon’s capital allocation priorities and strengthens its position to capitalize on future opportunities, as the company continues to focus on delivering attractive returns for shareholders.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. Its product portfolio includes oral health, pain relief, respiratory health, digestive health, and vitamins, minerals, and supplements, featuring well-known brands like Advil, Sensodyne, Panadol, and Centrum.
YTD Price Performance: 3.63%
Average Trading Volume: 24,597,353
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £35.41B
Find detailed analytics on HLN stock on TipRanks’ Stock Analysis page.